RVRebecca Voss

Rebecca Voss

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rebecca Voss has a total of 86 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical Experience of Using Integrated Whole Genome and Transcriptome Sequencing as A Framework for Pediatric and Adolescent Acute Myeloid Leukemia Diagnosis and Risk Assessment

    by Rebecca Voss, Lu Wang

    Pediatric acute myeloid leukemia (AML) exhibits distinct genetic characteristics, including unique driver alterations and mutations with prognostic and therapeutic implications. Cytogenetics study, along with Next Generation Sequencing (NGS) panel testing, have long been the standard for molecular diagnosis of AML. While these approaches enable diagnosis and prognosis determination in most cases, they have limitations—particularly in detecting emerging rare, recurrent genetic abnormalities. In this study, we systematically reviewed our real-time clinical experience with the diagnostic workup of pediatric AML using an integrated whole genome and whole transcriptome sequencing (iWGS-WTS) approach and compared the test results obtained from various methodologies, including whole genome sequencing (WGS), whole exome sequencing (WES), whole transcriptome sequencing (WTS), iWGS-WTS, cytogenetics, and targeted panel NGS. Our findings demonstrate that the iWGS-WTS approach improves the identification of clinically relevant genetic alterations, enhancing precise disease classification and risk assessment. Additionally, the iWGS-WTS approach streamlines sample acquisition and reduces testing redundancy, positioning it as a practical and superior alternative to traditional diagnostic methods in pediatric AML management.


  • Open Access

    Clinical experience of using integrated whole genome and transcriptome sequencing as a framework for pediatric and adolescent acute myeloid leukemia diagnosis and risk assessment

    by Rebecca K. Voss, Victor B. Pastor Loyola, Maria F. Cardenas, Priya Kumar, Jamie L. Maciaszek, Maria Namwanje, Jing Ma, Jennifer L. Neary, Meiling Jin, Masayuki Umeda, et al.

    Pediatric acute myeloid leukemia (AML) exhibits distinct genetic characteristics, including unique driver alterations and mutations with prognostic and therapeutic implications. Cytogenetics study, along with Next Generation Sequencing (NGS) panel testing, have long been the standard for molecular diagnosis of AML. While these approaches enable diagnosis and prognosis determination in most cases, they have limitations—particularly in detecting emerging rare, recurrent genetic abnormalities. In this study, we systematically reviewed our real-time clinical experience with the diagnostic workup of pediatric AML using an integrated whole genome and whole transcriptome sequencing (iWGS-WTS) approach and compared the test results obtained from various methodologies, including whole genome sequencing (WGS), whole exome sequencing (WES), whole transcriptome sequencing (WTS), iWGS-WTS, cytogenetics, and targeted panel NGS. Our findings demonstrate that the iWGS-WTS approach improves the identification of clinically relevant genetic alterations, enhancing precise disease classification and risk assessment. Additionally, the iWGS-WTS approach streamlines sample acquisition and reduces testing redundancy, positioning it as a practical and superior alternative to traditional diagnostic methods in pediatric AML management.


  • Top Cited Papers
    Open Access

    Age-dependent phenotypic and molecular evolution of pediatric MDS arising from GATA2 deficiency

    by Lili Kotmayer, Emilia J. Kozyra, Guolian Kang, Brigitte Strahm, Ayami Yoshimi, Sushree S. Sahoo, Victor B. Pastor, Enrico Attardi, Rebecca Voss, Luca Vinci, et al.

    GATA2 deficiency is an autosomal dominant transcriptopathy disorder with high risk for myelodysplastic syndrome (MDS). To elucidate genotype-phenotype associations and identify new genetic risk factors for MDS, we analyzed 218 individuals with germline heterozygous GATA2 variants. We observed striking age-dependent incidence patterns in GATA2-related MDS (GATA2-MDS), with MDS being absent in infants, rare before age 6 years, and steeply increasing in older children. Among 108 distinct GATA2 variants (67 novel), null mutations conferred a 1.7-fold increased risk for MDS, had earlier MDS onset compared to other variants (12.2 vs. 14.6 years, p = 0.009) and were associated with lymphedema and deafness. In contrast, intron 4 variants exhibited reduced penetrance and lower risk for MDS development. Analysis of the somatic landscape revealed unique patterns of clonal hematopoiesis. SETBP1 mutations occurred exclusively in patients with monosomy 7 and their frequency decreased with age. Conversely, the frequency of STAG2 mutations and trisomy 8 increased with age and appeared protective against early development of advanced MDS. Overall, the majority (73.9%) of mutation-positive cases harbored monosomy 7, suggesting it serves as a major driver in malignant progression. Our findings provide evidence for age-appropriate surveillance, and a foundation for genotype-driven risk stratification in GATA2 deficiency.


  • Open Access

    Integrated Whole Genome and Transcriptome Sequencing as a Framework for Pediatric and Adolescent AML Diagnosis and Risk Assessment

    by Lu Wang, Rebecca Voss, Victor Pastor, Maria Cardenas, Priyadarshini Kumar, Jamie Maciaszek, Maria Namwanje, Jing Ma, Jennifer Neary, Meiling Jin, et al.

    Pediatric acute myeloid leukemia (AML) exhibits distinct genetic characteristics, including unique driver alterations and mutations with prognostic and therapeutic significance. Emerging rare, recurrent genetic abnormalities and their associations with outcomes emphasize the need for high-throughput molecular diagnostic tools. Whole genome sequencing (WGS) reliably detects key AML biomarkers such as structural variants, mutations, and copy number alterations. Whole transcriptome sequencing (WTS) complements WGS by uncovering oncogene expression patterns, allele-specific expression, and gene expression signatures. In this study, we describe an integrated WGS and WTS clinical workflow for routine pediatric AML diagnosis and present a systematic evaluation of its application compared to conventional cytogenetics and standard molecular diagnostic methods. Our findings demonstrate that the integrated WGS and WTS (iWGS-WTS) approach improves the identification of clinically relevant genetic alterations, enhancing precise disease classification and risk assessment. Moreover, with advancements in workflow and bioinformatics pipelines, the testing turnaround time can be optimized to meet the demands of clinical decision-making, positioning iWGS-WTS as a practical and superior alternative to traditional diagnostic methods in pediatric AML management.